Stealth nanocarriers based sterosomes using PEG post-insertion process

DocumentFichier
Fichier pdf chargé le 25/02/2017 à 09:30:26
Accès identifié
(version éditeur)
Request
SupplémentCommentaireFichier
Fichier pdf chargé le 25/02/2017 à 09:30:26
Accès identifié
Supplementary informationRequest
TitreStealth nanocarriers based sterosomes using PEG post-insertion process
Type de publicationArticle de revue
AuteurCieślak, Anna , Wauthoz, Nathalie , Nieto Orellana, Alejandro , Lautram, Nolwenn , Bejaud, Jérôme , Hureaux, José , Lafleur, Michel , Benoît, Jean-Pierre , Salomon, Claudio J , Bastiat, Guillaume
PaysPays-Bas
EditeurElsevier
VilleAmsterdam
TypeArticle scientifique dans une revue à comité de lecture
Année2017
LangueAnglais
DateJuin 2017
Pagination31-38
Volume115
Titre de la revueEuropean Journal of Pharmaceutics and Biopharmaceutics
ISSN0939-6411
Mots-clésBiodistribution, CH50 experiment, Macrophage uptake, PEG, Sterosomes
Résumé en anglais

Sterosomes (STEs), a new and promising non-phospholipidic liposome platform based on palmitic acid (PA) and cholesterol (Chol) mixtures, need to have polyethylene glycol (PEG) chains grafted to their surface in order to obtain long-circulating nanocarriers in the blood stream. A post-insertion method was chosen to achieve this modification. The post-insertion process of PEG-modified distearoylphosphoethanolamine (DSPE-PEG) was monitored using the zeta potential value of STEs. Various conditions including PEG chain length and the DSPE-PEG/PA-Chol ratio, were explored. Zeta potential of STEs changed from about -40mV for non-modified STEs to values close to 0 mV by the end of the process, i.e. for PEG-modified STEs. The kinetics of DSPE-PEG insertion and the stability of the resulting PEG-modified STEs were not considerably influenced, within the investigated range, by changes in PEG chain lengths and in DSPE-PEG/PA-Chol proportion. The post-insertion of PEG chains reduced in vitro complement activation as well as in vitro macrophage uptake compared to the non-modified STEs. Moreover, longer blood circulation time in mice was established for PEG-modified STEs intravenously injected compared to non-modified STEs. These results establish that post-insertion process of PEG chains to STEs is a promising strategy for developing long-term circulating drug delivery nanocarriers.

URL de la noticehttp://okina.univ-angers.fr/publications/ua15629
DOI10.1016/j.ejpb.2017.02.008
Lien vers le document

http://www.sciencedirect.com/science/article/pii/S0939641117301996

Titre abrégéEur. j. pharm. biopharm.